Observational Study of Canakinumab Treatment in Patients with Familial Mediterranean Fever and Stills Disease Including SJIA and Adult-Onset Stills Disease

What this Trial Is About

Researchers are evaluating the treatment patterns, long-term clinical outcomes, and demographic characteristics of patients diagnosed with Familial Mediterranean Fever FMF and Stills disease, including systemic juvenile idiopathic arthritis SJIA and adult-onset Stills disease AOSD, who have received canakinumab for at least six months. The study aims to understand how canakinumab is used in real-world settings among these patient groups and to assess their responses over time. The study is observational and does not involve assigning any treatments. It includes patients who have been prescribed canakinumab prior to October 2021 and have used it for at least six months. The patient cohorts consist of those with FMF, SJIA, and AOSD. Researchers collect data retrospectively on clinical characteristics, treatment regimens, and medication use patterns over a period of at least three years following the start of canakinumab treatment. Participants medical records and treatment histories are reviewed to measure outcomes such as rates of clinically inactive disease, remission, response levels, and treatment discontinuation reasons over up to three years. Additional assessments include hospitalizations, medical visits, diagnostic and laboratory tests, and quality of life scores. This comprehensive data collection helps characterize patient experiences and treatment effects under usual care conditions without altering the therapy received.

A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients